Ixekizumab drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.
The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed biosimilar drug.
Find and order your therapeutic molecules through smart filters
Up to 10 batches of original drugs for examining batch-to-batch variations
Up to 80% less compared to the original pharmaceutical price
Shipment within days worldwide according to GDP-standards
Up to 80% less compared to the original pharmaceutical price
| Drug name | Taltz® |
| INN | Ixekizumab |
| API type | Ixekizumab is a monoclonal antibody, produced in CHO cells by recombinant DNA technology. |
| Pharmacotherapeutic group | Immunosuppressants, interleukin inhibitors |
| ATC code | L04AC13 |
| Target of antibody | 17A (both IL-17A and IL-17A/F) |
| General function | Ixekizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
| Short description | |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Ixekizumab is an IgG4 monoclonal antibody that binds with high affinity (< 3 pM) and specificity to interleukin 17A (both IL-17A and IL-17A/F). Elevated concentrations of IL-17A have been implicated in the pathogenesis of psoriasis by promoting keratinocyte proliferation and activation, as well as in the pathogenesis of psoriatic arthritis and axial spondyloarthritis by driving inflammation leading to erosive bone damage and pathological new bone formation. Neutralisation of IL-17A by Ixekizumab inhibits these actions. Ixekizumab does not bind to ligands IL-17B, IL-17C, IL-17D, IL-17E or IL-17F. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | Ixekizumab modulates biological responses that are induced or regulated by IL-17A. Based on psoriatic skin biopsy data from a phase I study, there was a dose-related trend toward decreased epidermal thickness, a number of proliferating keratinocytes, T cells, and dendritic cells, as well as reductions in local inflammatory markers from baseline to day 43. As a direct consequence of treatment with Ixekizumab reduces erythema, induration and desquamation present in plaque psoriasis lesions. |
| Original license holder | Eli Lilly and Company (Ireland) Limited Dunderrow Kinsale Co. Cork Ireland |
| Marketing authorisation numbers | EU/1/15/1085/001 EU/1/15/1085/002 EU/1/15/1085/003 |
| Marketing authorisation holder | Eli Lilly and Company (Ireland) Limited Dunderrow Kinsale Co. Cork Ireland |
| Name of the manufacturer of the biological active substance | Eli Lilly Kinsale (Ireland) Limited Dunderrow Kinsale Co. Cork Ireland |
| Name and address of the manufacturer(s) responsible for batch release | Eli Lilly Italia S.p.A. Via Gramsci 731/733 50019 Sesto Fiorentino (FI) Italy |
| Max shelf life | 2 years |
| Storage conditions | 2°C – 8°C |
| List of excipients | Sucrose Polysorbate 80 Water for injections Sodium hydroxide may be used to adjust pH |
Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.
Evidentic GmbH
Am Mühlenberg 10
14476 Potsdam | Germany
